Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer-Reference-Cited by-同舟云学术

Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer

Published:2024 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Wasamoto Satoshi¹,Imai Hisao²³,Tsuda Takeshi⁴,Nagai Yoshiaki⁵,Kishikawa Takayuki⁶,Ono Akihiro⁷,Masubuchi Ken³,Umeda Yukihiro⁸,Yamada Yutaka⁹,Nakagawa Junichi¹⁰,Yui Takaya¹,Taniguchi Hirokazu⁴,Kaira Kyoichi²,Kagamu Hiroshi²

Affiliation:

1. Division of Respiratory Medicine, Saku Central Hospital Advanced Care Center, Japan

2. Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Japan

3. Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Japan

4. Division of Respiratory Medicine, Toyama Prefectural Central Hospital, Japan

5. Department of Respiratory Medicine, Jichi Medical University, Saitama Medical Center, Japan

6. Division of Thoracic Oncology, Tochigi Cancer Center, Japan

7. Division of Internal Medicine, Kiryu Kosei General Hospital, Japan

8. Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan

9. Division of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Japan

10. Division of Respiratory Medicine, National Hospital Organization Takasaki General Medical Center, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_3649-24/_pdf

Reference41 articles.

1. 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 71: 7-33, 2021.

2. 2. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66: 271-289, 2016.

3. 3. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 28: 2191-2197, 2010.

4. 4. Sacher AG, Le LW, Leighl NB, Coate LE. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol 8: 366-368, 2013.

5. 5. Pang HH, Wang X, Stinchcombe TE, et al. Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012. J Clin Oncol 34: 3992-3999, 2016.